| |
|
|
|
|
|
 |
| |
|
¸ñƾĸ½¶200mg(¾Æ¼¼Æ¿½Ã½ºÅ×ÀÎ) Moktin Cap. 200mg
|
|
ÀϹÝÀǾàǰ | ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| ¾ÈÀü¼º ¼ÇÑ |
[ÀǾàǰ ¾ÈÀü¼º ¼ÇÑ Á¶È¸]
|
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
643501030[A21402951]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\64 ¿ø/1ĸ½¶(2025.02.01)(ÇöÀç¾à°¡)
\64 ¿ø/1ĸ½¶(2017.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
Èò»ö ºÐ¸»ÀÌ µç »ó, ÇÏ ¿¬Ã»»öÀÇ °æÁúĸ½¶Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
300ĸ½¶/º´ |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 200¹Ð¸®±×·¥ |
300 ĸ½¶ |
º´ |
8806435010308 |
8806435010353 |
|
| 200¹Ð¸®±×·¥ |
30 ĸ½¶ |
º´ |
8806435010308 |
8806435010346 |
|
| 200¹Ð¸®±×·¥ |
500 ĸ½¶ |
º´ |
8806435010308 |
8806435010339 |
|
| 200¹Ð¸®±×·¥ |
100 ĸ½¶ |
º´ |
8806435010308 |
8806435010322 |
|
| 200¹Ð¸®±×·¥ |
10 ĸ½¶ |
PTP |
8806435010308 |
8806435010315 |
|
|
| ÁÖ¼ººÐÄÚµå |
101804ACH
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
´ÙÀ½ Áúȯ¿¡¼ÀÇ °´´ã¹èÃâ°ï¶õ : ±Þ¤ý¸¸¼º±â°üÁö¿°, ±â°üÁöõ½Ä, Èĵο°, ºÎºñµ¿¿°, ³¶¼º¼¶À¯Áõ
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¾Æ¼¼Æ¿½Ã½ºÅ×ÀÎÀ¸·Î¼ ´ÙÀ½ ¿ë·®À» ½ÄÀü¿¡ ¼Ò·®ÀÇ ¹°°ú ÇÔ²² º¹¿ëÇÑ´Ù.
1. ±Þ¼ºÁúȯ
¼ºÀÎ : 1ȸ 200 mg 1ÀÏ 3ȸ
¼Ò¾Æ : 6 ¢¦ 14¼¼ 1ȸ 200 mg 1ÀÏ 2ȸ
2. ¸¸¼ºÁúȯ
¼ºÀÎ : 1ȸ 200 mg 1ÀÏ 2ȸ
¼Ò¾Æ : 6 ¢¦ 14¼¼ 1ȸ 100 mg 1ÀÏ 3ȸ
3. ³¶¼º¼¶À¯Áõ
¼Ò¾Æ : 6¼¼ ÀÌ»ó 1ȸ 200 mg 1ÀÏ 3ȸ
|
| ±Ý±â |
1) ÀÌ ¾à ¶Ç´Â ÀÌ ¾àÀÇ ±¸¼º¼ººÐ¿¡ °ú¹Î¹ÝÀÀ ȯÀÚ
2) À§•½ÊÀÌÁöÀå±Ë¾ç ȯÀÚ
3) 2¼¼ ¹Ì¸¸ ¿µ¾Æ
4) ÀÌ ¾àÀº À¯´çÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î, °¥¶ôÅä¿À½º ºÒ³»¼º(galactose intolerance), Lapp À¯´çºÐÇØÈ¿¼Ò °áÇÌÁõ(Lapp lactase deficiency) ¶Ç´Â Æ÷µµ´ç-°¥¶ôÅä¿À½º Èí¼öÀå¾Ö(glucose-galactose malabsorption) µîÀÇ À¯ÀüÀûÀÎ ¹®Á¦°¡ Àִ ȯÀÚ¿¡°Ô´Â Åõ¿©ÇÏ¸é ¾È µÈ´Ù. |
| ½ÅÁßÅõ¿© |
1) ÀӺΠ: ÀӺο¡ ´ëÇÑ ÀûÀýÇÑ ¿¬±¸°¡ ¾øÀ¸¹Ç·Î ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ¿©¼º¿¡´Â ¹Ýµå½Ã ÇÊ¿äÇÑ °æ¿ì¿¡¸¸ Åõ¿©ÇÑ´Ù.
2) ¼öÀ¯ºÎ : ÀÌ ¾àÀÌ ¸ðÀ¯·Î ºÐºñµÇ´ÂÁö ¾Ë·ÁÁöÁö ¾Ê¾ÒÀ¸³ª ¸¹Àº ¾àµéÀÌ ¸ðÀ¯·Î ºÐºñµÇ¹Ç·Î ¼öÀ¯ºÎ¿¡ Åõ¿©ÇÒ °æ¿ì¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. |
| ÀÌ»ó¹ÝÀÀ |
´ÙÀ½°ú °°À» °æ¿ì ÀÌ ¾àÀÇ º¹¿ëÀ» Áï°¢ ÁßÁöÇϰí ÀÇ»ç, Ä¡°úÀÇ»ç, ¾à»ç¿Í »óÀÇÇÒ °Í. »ó´ã½Ã °¡´ÉÇÑ ÇÑ ÀÌ Ã·ºÎ¹®¼¸¦ ¼ÒÁöÇÒ °Í.
1) ¼Òȱâ°è : µå¹°°Ô ±¸¿ª, ±¸Åä, ±¸³»¿°, °¡½¿¾²¸², ¼³»ç µî
2) °ú¹Î¹ÝÀÀ : µå¹°°Ô µÎµå·¯±â, °¡·Á¿ò, ¹ßÁø, µÎÅë, À̸í, ±â°üÁö°æ·Ã(ƯÈ÷ õ½Ä ȯÀÚ) µî
3) µå¹°°Ô ºó¸Æ, °íÇ÷¾Ð. ¸Å¿ì µå¹°°Ô ¾Æ³ªÇʶô½Ã½º
4) ±¹³» ÀÚ¹ßÀû À¯ÇØ»ç·Ê º¸°íÀÚ·á(1989 ¢¦ 2013 »ó¹Ý±â)¸¦ ºÐ¼®ÇÑ °á°ú, À¯ÇØ»ç·Ê°¡ º¸°íµÈ ´Ù¸¥ ÀǾàǰ¿¡¼ ¹ß»ýÇÑ À¯ÇØ»ç·Ê¿¡ ºñÇØ Åë°èÀûÀ¸·Î À¯ÀÇÇÏ°Ô ¸¹ÀÌ º¸°íµÈ À¯ÇØ»ç·Ê´Â ´ÙÀ½°ú °°ÀÌ ³ªÅ¸³µ´Ù. ´Ù¸¸, À̷μ °ð ÇØ´ç¼ººÐ°ú ´ÙÀ½ÀÇ À¯ÇØ»ç·Ê °£¿¡ Àΰú°ü°è°¡ ÀÔÁõµÈ °ÍÀ» ÀǹÌÇÏ´Â °ÍÀº ¾Æ´Ï´Ù.
¡¤ È£Èí°ï¶õ
|
| Off-label Usage |
[Á¶È¸]
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| ¼ººÐÄÚµå |
M050972/¾Æ¼¼Æ¿½Ã½ºÅ×ÀÎ 200¹Ð¸®±×·¥ /
|
| ÁÖ¼ººÐÄÚµå |
101804ACH
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| ´ëÇ¥ÄÚµå |
8806435010308 |
| BIT ¾àÈ¿ºÐ·ù |
ÁøÇذŴãÁ¦ & ±âħ°¨±â¾à (Cough & Cold remedies)
|
| ATC ÄÚµå |
Acetylcysteine / R05CB01
[ÄÚµåºÐ·ù»ó¼¼¼³¸í]
[ATCÄÚµå¿¹Ãø]
|
| º¹ÁöºÎºÐ·ùÄÚµå |
222 (ÁøÇذŴãÁ¦ )
|
| ÀǾàǰ ¹ÙÄÚµåÁ¤º¸ |
³»¿ëº¸±â
¸ñƾݼ¿(¾Æ¼¼Æ¿½Ã½ºÅ×ÀÎ)(¼öÃâ¸í:¹ÂÄÚºê·ÐÄ¡)/ A21402951
Á¦Ç°±Ô°Ý: 200¹Ð¸®±×·¥/Á¦Ç°¼ö·®: 10/Á¦Çü: Á¤
Æû¸ñ±âÁØÄÚµå: 199902656 /´ëÇ¥ÄÚµå: 8806435010308/Ç¥ÁØÄÚµå: 8806435010315
±¸¹ÙÄÚµå: -/ºñ°í:-
¸ñƾݼ¿(¾Æ¼¼Æ¿½Ã½ºÅ×ÀÎ)(¼öÃâ¸í:¹ÂÄÚºê·ÐÄ¡)/ A21402951
Á¦Ç°±Ô°Ý: 200¹Ð¸®±×·¥/Á¦Ç°¼ö·®: 100/Á¦Çü: Á¤
Æû¸ñ±âÁØÄÚµå: 199902656 /´ëÇ¥ÄÚµå: 8806435010308/Ç¥ÁØÄÚµå: 8806435010322
±¸¹ÙÄÚµå: 8806029115327/ºñ°í:-
¸ñƾݼ¿(¾Æ¼¼Æ¿½Ã½ºÅ×ÀÎ)(¼öÃâ¸í:¹ÂÄÚºê·ÐÄ¡)/ A21402951
Á¦Ç°±Ô°Ý: 200¹Ð¸®±×·¥/Á¦Ç°¼ö·®: 500/Á¦Çü: Á¤
Æû¸ñ±âÁØÄÚµå: 199902656 /´ëÇ¥ÄÚµå: 8806435010308/Ç¥ÁØÄÚµå: 8806435010339
±¸¹ÙÄÚµå: 8806029115310/ºñ°í:-
¸ñƾݼ¿(¾Æ¼¼Æ¿½Ã½ºÅ×ÀÎ)(¼öÃâ¸í:¹ÂÄÚºê·ÐÄ¡)/ A21402951
Á¦Ç°±Ô°Ý: 200¹Ð¸®±×·¥/Á¦Ç°¼ö·®: 30/Á¦Çü: ĸ½¶
Æû¸ñ±âÁØÄÚµå: 199902656 /´ëÇ¥ÄÚµå: 8806435010308/Ç¥ÁØÄÚµå: 8806435010346
±¸¹ÙÄÚµå: 8806029115389/ºñ°í:-
|
ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä |
[ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä]
|
| Drugs By Indication |
[Àüüº¸±â]
|
| Drugs By Classification |
[Àüüº¸±â]
|
|
|
 | Á¦Ç°Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
643501030[A21402951]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\64 ¿ø/1ĸ½¶(2025.02.01)(Ãֽžడ)
\64 ¿ø/1ĸ½¶(2017.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
|
| Á¦Ç°¼º»ó |
Èò»ö ºÐ¸»ÀÌ µç »ó, ÇÏ ¿¬Ã»»öÀÇ °æÁúĸ½¶Á¦
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| ´ëü°ü·Ã |
ºñ±³¿ëÃâ ½ÃÇè¿Ï·á |
| Æ÷À塤À¯Åë´ÜÀ§ |
300ĸ½¶/º´ |
| º¸°ü¹æ¹ý |
±â¹Ð¿ë±â, ½Ç¿Âº¸°ü(1-30¡É) |
µ¿ÀÏÁÖ¼ººÐÄÚµå °Ë»ö¼øÀ§ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Brandname Á¤º¸ |
Acetylcysteine
Brand Names/Synonyms
- (R)-2-Amino-3-mercaptopropanoic acid
- (R)-Cysteine
- 2-Amino-3-mercaptopropionic acid
- C
- Cys
- Cystein
- Cysteine, L-
- Half-cystine
- L-(+)-Cysteine
- L-Alanine, 3-mercapto-
- L-Cys
- L-cysteine
- N-acetyl-L-cysteine (NAC)
- Propanoic acid, 2-amino-3-mercapto-, (R)-
- Thioserine
- acetylcysteine
- b-Mercaptoalanine
- carbocysteine
Brand Name Mixtures
- Amino Acid Concentrate Inj (Arginine Hcl + Calcium Chloride + Dexpanthenol + Dextrose + Dl-Methionine + Glutamic Acid + Histidine Hcl + Isoleucine + L-Cysteine Hydrochloride + L-Lysine Hydrochloride + Leucine + Magnesium Sulfate + Nicotinamide + Phenylalanine + Potassium Chloride + Sodium Acetate + Threonine + Tryptophan + Valine + Vitamin B1 (Thiamine) + Vitamin B12 + Vitamin B2 (Riboflavin) + Vitamin B6 (Pyridoxine))
- Amino Acid Inj (Arginine + Calcium Chloride + D-Pantothenic Acid (Calcium D-Pantothenate) + Dextrose + Histidine + Isoleucine + L-Cysteine Hydrochloride + Leucine + Lysine + Magnesium Sulfate + Methionine + Nicotinamide + Phenylalanine + Potassium Chloride + Pyridoxine Hydrochloride + Sodium Acetate + Threonine + Tryptophan + Valine + Vitamin B1 + Vitamin B12 + Vitamin B2)
- Amino Lite (Arginine + Calcium Chloride + Dextrose + Isoleucine + L-Cysteine Hydrochloride + L-Histidine Hcl + L-Lysine Hydrochloride + Leucine + Magnesium Sulfate + Methionine + Nicotinic Acid + Phenylalanine + Potassium Chloride + Pyridoxine Hydrochloride + Sodium Glutamate + Thiamine Hydrochloride + Threonine + Tryptophan + Valine + Vitamin B12 + Vitamin B2 (Riboflavin 5'-Phosphate Sodium))
- Aminoderm Poudre (Glycine + L-Cysteine + Neomycin Sulfate + Threonine)
- Bvs Amino Acid Solution Inj (Arginine Hcl + Calcium Chloride + Dexpanthenol + Dextrose + Dl-Isoleucine + L-Cysteine Hydrochloride + L-Histidine Hcl + L-Lysine Hydrochloride + Leucine + Magnesium Sulfate + Methionine + Nicotinamide + Phenylalanine + Potassium Chloride + Pyridoxine Hydrochloride + Sodium Acetate Hemodialysis + Sodium Glutamate + Threonine + Tryptophan + Valine + Vitamin B1 + Vitamin B12 + Vitamin B2)
- Cicatrin Powder (Bacitracin Zinc + Glycine + L-Cysteine + Neomycin Sulfate + Threonine)
- Nephramine Liq Iv (Dl-Methionine + Histidine + Isoleucine + L-Cysteine (L-Cysteine Hydrochloride) + Leucine + Lysine (Lysine Acetate) + Phenylalanine + Sodium Bisulfite + Threonine + Tryptophan + Valine)
- Primene 10% (Glutamic Acid + Glycine + Histidine + L-Alanine + L-Arginine + L-Aspartic Acid + L-Cysteine + L-Isoleucine + L-Leucine + L-Lysine + L-Ornithine Dihydrochloride + L-Phenylalanine + L-Proline + L-Threonine + L-Tyrosine + L-Valine + Methionine + Serine + Taurine + Tryptophan)
- Primene 10%-Liq Iv (Glutamic Acid + Glycine + Histidine + L-Alanine + L-Arginine + L-Aspartic Acid + L-Cysteine Hydrochloride + L-Isoleucine + L-Leucine + L-Lysine + L-Ornithine + L-Phenylalanine + L-Proline + L-Threonine + L-Tyrosine + L-Valine + Methionine + Serine + Taurine + Tryptophan)
- Stv Amino Acid Sol Inj (Arginine Hcl + Calcium Chloride + Dexpanthenol + Dextrose + Dl-Methionine + Glutamic Acid + Histidine Hcl + Isoleucine + L-Cysteine Hydrochloride + L-Lysine Hydrochloride + Leucine + Magnesium Sulfate + Nicotinamide + Phenylalanine + Potassium Chloride + Pyridoxine Hydrochloride + Sodium Acetate + Threonine + Tryptophan + Valine + Vitamin B1 (Thiamine) + Vitamin B12 + Vitamin B2 (Riboflavin))
- Vamin 18 Electrolyte-Free (Glutamic Acid + Glycine + Histidine + L-Alanine + L-Arginine + L-Aspartic Acid + L-Cysteine + L-Isoleucine + L-Leucine + L-Lysine (Lysine Acetate) + L-Phenylalanine + L-Proline + L-Threonine + L-Tyrosine + L-Valine + Methionine + Serine + Tryptophan)
- Vamin N (Calcium Chloride + Glutamic Acid + Glycine + Histidine + L-Alanine + L-Arginine + L-Aspartic Acid + L-Cysteine (L-Cysteine Hydrochloride) + L-Isoleucine + L-Leucine + L-Lysine (L-Lysine Hydrochloride) + L-Phenylalanine + L-Proline + L-Threonine + L-Tyrosine + L-Valine + Magnesium Sulfate + Methionine + Potassium Chloride + Potassium Hydroxide + Serine + Sodium Hydroxide + Tryptophan)
Chemical IUPAC Name2-amino-3-sulfanyl-propanoic acid
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Acetylcysteine¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Acetylcysteine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Acetylcysteine may protect against acetaminophen overdose-induced hepatotoxicity by maintaining or restoring hepatic concentrations of glutathione. Glutathione is required to inactivate an intermediate metabolite of acetaminophen that is thought to be hepatotoxic. In acetaminophen overdose, excessive quantities of this metabolite are formed because the primary metabolic (glucuronide and sulfate conjugation) pathways become saturated. Acetylcysteine may act by reducing the metabolite to the parent compound and/or by providing sulfhydryl for conjugation of the metabolite. Experimental evidence also suggests that a sulfhydryl-containing compound such as acetylcysteine may also directly inactivate the metabolite. Inhalation - Acetylcysteine exerts its mucolytic action through its free sulfhydryl group, which opens the disulfide bonds and lowers mucus viscosity. This action increases with increasing pH and is most significant at pH 7 to 9. The mucolytic action of acetylcysteine is not affected by the presence of DNA.
|
| Pharmacology |
Acetylcysteine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Acetylcysteine has been shown to reduce the extent of liver injury following acetaminophen overdose. It is most effective when given early, with benefit seen principally in patients treated within 8-10 hours of the overdose. Acetylcysteine likely protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite.
|
| Protein Binding |
Acetylcysteine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 83%
|
| Half-life |
Acetylcysteine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 5.6 hours (adults), 11 hours (neonates)
|
| Absorption |
Acetylcysteine¿¡ ´ëÇÑ Absorption Á¤º¸ Bioavailability is 6??0% following oral administration and less than 3% following topical administration.
|
| Pharmacokinetics |
AcetylcysteineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÃÖ´ë Á¡¾×¿ëÇØÈ¿°ú ¹ßÇö½Ã°£
- ÀÛ¿ëÁö¼Ó½Ã°£ : 1½Ã°£ ÀÌ»ó
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£
- ºÐÆ÷¿ëÀû
- ´Ü¹é°áÇÕ
- ¹Ý°¨±â
- ȯ¿øÇü acetylcysteine : 2½Ã°£
- Àüü acetylcysteineÀ¸·Î¼ 5.5 ½Ã°£
|
| Biotransformation |
Acetylcysteine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic. Deacetylated by the liver to cysteine and subsequently metabolized.
|
| Toxicity |
Acetylcysteine¿¡ ´ëÇÑ Toxicity Á¤º¸ Single intravenous doses of acetylcysteine at 1000 mg/kg in mice, 2445 mg/kg in rats, 1500 mg/kg in guinea pigs, 1200 mg/kg in rabbits and 500 mg/kg in dogs were lethal. Symptoms of acute toxicity were ataxia, hypoactivity, labored respiration, cyanosis, loss of righting reflex and convulsions.
|
| Drug Interactions |
Acetylcysteine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Description |
Acetylcysteine¿¡ ´ëÇÑ Description Á¤º¸ The N-acetyl derivative of cysteine. It is used as a mucolytic agent to reduce the viscosity of mucous secretions. It has also been shown to have antiviral effects in patients with HIV due to inhibition of viral stimulation by reactive oxygen intermediates. [PubChem]
|
| Drug Category |
Acetylcysteine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antiviral AgentsExpectorantsFree Radical Scavengers
|
| Smiles String Canonical |
Acetylcysteine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(=O)NC(CS)C(O)=O
|
| Smiles String Isomeric |
Acetylcysteine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC(=O)N[C@@H](CS)C(O)=O
|
| InChI Identifier |
Acetylcysteine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1/f/h6,8H
|
| Chemical IUPAC Name |
Acetylcysteine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2R)-2-acetamido-3-sulfanylpropanoic acid
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-09-30
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
The database contains the following fields: The generic name of each chemical For module A10 (liver enzyme composite module): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method) Number of endpoints at which each compound is marginally active (M) Number of endpoints at which each compound is active (A) For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method) Number of ADR reports for each compound, given as <4 or ¡Ã4 Reporting Index value for each compound, except where no shipping units were available (NSU) Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period. ACETYLCYSTEINE[GGT Increase][Composite Activity](Score) NA(Marginal) 0(Active) 1[Alkaline Phosphatase Increase](Activity Score) NA(Number of Rpts) NA(Index value) NA[SGOT Increase](Activity Score) NA(Number of Rpts) NA(Index value) NA[SGPT Increase](Activity Score) A(Number of Rpts) ¡Ã4(Index value) 4.8[LDH Increase](Activity Score) NA(Number of Rpts) NA(Index value) NA[GGT Increase](Activity Score) NA(Number of Rpts) NA(Index value) NA
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|